Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase
NextSource Materials Executes Letter of Intent with Hanwa and JOGMEC for a US$30 Million Strategic Investment in UAE Battery Anode Facility
Harvest Gold Meets 2025 Mosseau Exploration Expenditure Obligation Pursuant To Its Mosseau Mineral Agreement With Vior Gold Corporation Inc.
